Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Edwards Lifesciences CorpEW · Entity 3026 | CVP, TAVR | October 08, 2026 | October 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Edwards Lifesciences Corp
Report date October 08, 2026 · Filed October 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 40,033.9103 |
Ending reported balance
After 2026-10-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-08 · Exercise / conversion · Acquired 619 · Balance 40,652.9103 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026. Row 2 · 2026-10-08 · Sale · Disposed 619 · Balance 40,033.9103 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026. |
| Employee Stock Option (Right to Acquire)SEC Table II · derivative / convertible security · Conversion / exercise price $72.68 · Expires 2027-05-06 | Direct | 3,095 |
Reported balance
After 2026-10-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-08 · Exercise / conversion · Disposed 619 · Balance 3,095 |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 09, 2024 Filed Apr 9, 2024 21:33 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 857 | $92.34 | $79,135.38 |
DisclosureSEC source: 0001225208-24-005020 · doc4.xml · nonDerivative · entry 2 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,487.7443 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2023. Read SEC document |
| April 09, 2024 Filed Apr 9, 2024 21:33 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 857 | $36.75 | $31,494.75 |
DisclosureSEC source: 0001225208-24-005020 · doc4.xml · nonDerivative · entry 1 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,344.7443 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2023. Read SEC document |
| March 07, 2024 Filed Mar 7, 2024 23:22 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 1,715 | $0.00 Strike: $36.75 | $0.00 |
DisclosureSEC source: 0001225208-24-003866 · doc4.xml · derivative · entry 3 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,714 Underlying: Common Stock · 1,715 shares Expires 2024-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 07, 2024 Filed Mar 7, 2024 23:22 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 1,715 | $90.98 | $156,030.70 |
DisclosureSEC source: 0001225208-24-003866 · doc4.xml · nonDerivative · entry 2 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,213.2105 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2023. Read SEC document |
| March 07, 2024 Filed Mar 7, 2024 23:22 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 1,715 | $36.75 | $63,026.25 |
DisclosureSEC source: 0001225208-24-003866 · doc4.xml · nonDerivative · entry 1 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,928.2105 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2023. Read SEC document |
| February 18, 2024 Filed Feb 20, 2024 22:49 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 188 | $86.10 | $16,186.80 |
DisclosureSEC source: 0001225208-24-002520 · doc4.xml · nonDerivative · entry 3 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,213.2105 Read SEC document |
| February 17, 2024 Filed Feb 20, 2024 22:49 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 150 | $86.10 | $12,915.00 |
DisclosureSEC source: 0001225208-24-002520 · doc4.xml · nonDerivative · entry 2 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,401.2105 Read SEC document |
| February 16, 2024 Filed Feb 20, 2024 22:49 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 207 | $86.04 | $17,810.28 |
DisclosureSEC source: 0001225208-24-002520 · doc4.xml · nonDerivative · entry 1 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,551.2105 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.